271 related articles for article (PubMed ID: 31711450)
21. Effects of second-line anti-tuberculosis drugs on the intestinal microbiota of patients with rifampicin-resistant tuberculosis.
Wu C; Yi H; Hu Y; Luo D; Tang Z; Wen X; Zhang Y; Tang M; Zhang L; Wu S; Chen M
Front Cell Infect Microbiol; 2023; 13():1127916. PubMed ID: 37187470
[TBL] [Abstract][Full Text] [Related]
22. Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis.
Gao J; Ma Y; Du J; Zhu G; Tan S; Fu Y; Ma L; Zhang L; Liu F; Hu D; Zhang Y; Li X; Li L; Li Q
BMC Pulm Med; 2016 Feb; 16():26. PubMed ID: 26846562
[TBL] [Abstract][Full Text] [Related]
23. Decreasing antibiotic use, the gut microbiota, and asthma incidence in children: evidence from population-based and prospective cohort studies.
Patrick DM; Sbihi H; Dai DLY; Al Mamun A; Rasali D; Rose C; Marra F; Boutin RCT; Petersen C; Stiemsma LT; Winsor GL; Brinkman FSL; Kozyrskyj AL; Azad MB; Becker AB; Mandhane PJ; Moraes TJ; Sears MR; Subbarao P; Finlay BB; Turvey SE
Lancet Respir Med; 2020 Nov; 8(11):1094-1105. PubMed ID: 32220282
[TBL] [Abstract][Full Text] [Related]
24. Association of metformin administration with gut microbiome dysbiosis in healthy volunteers.
Elbere I; Kalnina I; Silamikelis I; Konrade I; Zaharenko L; Sekace K; Radovica-Spalvina I; Fridmanis D; Gudra D; Pirags V; Klovins J
PLoS One; 2018; 13(9):e0204317. PubMed ID: 30261008
[TBL] [Abstract][Full Text] [Related]
25. Mycobacterium tuberculosis infection in solid organ transplant recipients: experience from a single center in China.
Zhang XF; Lv Y; Xue WJ; Wang B; Liu C; Tian PX; Yu L; Chen XY; Liu XM
Transplant Proc; 2008 Jun; 40(5):1382-5. PubMed ID: 18589112
[TBL] [Abstract][Full Text] [Related]
26. The Microbiome and Tuberculosis: Early Evidence for Cross Talk.
Namasivayam S; Sher A; Glickman MS; Wipperman MF
mBio; 2018 Sep; 9(5):. PubMed ID: 30228238
[TBL] [Abstract][Full Text] [Related]
27. Metabolic and Immune Consequences of Antibiotic Related Microbiome Alterations during first-line Tuberculosis Treatment in Bamako, Mali.
Diallo D; Sun S; Somboro AM; Baya B; Kone A; Diarra B; Nantoume M; Koloma I; Diakite M; Holl J; Maiga AI; Seydi M; Theron G; Hou L; Fodor A; Maiga M
Res Sq; 2023 Aug; ():. PubMed ID: 37609282
[TBL] [Abstract][Full Text] [Related]
28. Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.
Saktiawati AM; Sturkenboom MG; Stienstra Y; Subronto YW; Sumardi ; Kosterink JG; van der Werf TS; Alffenaar JW
J Antimicrob Chemother; 2016 Mar; 71(3):703-10. PubMed ID: 26661397
[TBL] [Abstract][Full Text] [Related]
29. Twice-weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa.
Davies GR; Connolly C; Sturm AW; McAdam KP; Wilkinson D
AIDS; 1999 May; 13(7):811-7. PubMed ID: 10357380
[TBL] [Abstract][Full Text] [Related]
30. Antibiotic treatment for Tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed.
Wipperman MF; Fitzgerald DW; Juste MAJ; Taur Y; Namasivayam S; Sher A; Bean JM; Bucci V; Glickman MS
Sci Rep; 2017 Sep; 7(1):10767. PubMed ID: 28883399
[TBL] [Abstract][Full Text] [Related]
31. Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure.
Ambreen A; Jamil M; Rahman MAU; Mustafa T
BMC Infect Dis; 2019 Oct; 19(1):923. PubMed ID: 31666021
[TBL] [Abstract][Full Text] [Related]
32. A comparison of intestinal microbiota in a population of low-risk infants exposed and not exposed to intrapartum antibiotics: The Baby & Microbiota of the Intestine cohort study protocol.
Simioni J; Hutton EK; Gunn E; Holloway AC; Stearns JC; McDonald H; Mousseau A; Schertzer JD; Ratcliffe EM; Thabane L; Surette MG; Morrison KM
BMC Pediatr; 2016 Nov; 16(1):183. PubMed ID: 27832763
[TBL] [Abstract][Full Text] [Related]
33. Short-course Regimen for Subsequent Treatment of Pulmonary Tuberculosis: A Prospective, Randomized, Controlled Multicenter Clinical Trial in China.
Yan L; Kan X; Zhu L; Xu K; Yin J; Jie L; Li Y; Yue J; Cui W; Du J; Wang L; Tan S; Jiang X; Zeng Z; Xu S; Wang L; Chen Y; He W; Gao X; Bai D; Zhao C; Yan X; Zhu Y; Fan Y; Xie L; Deng A; Zhang Q; Xiao H
Clin Ther; 2018 Mar; 40(3):440-449. PubMed ID: 29519716
[TBL] [Abstract][Full Text] [Related]
34. Dysbiosis of the intestinal microbiota in neurocritically ill patients and the risk for death.
Xu R; Tan C; Zhu J; Zeng X; Gao X; Wu Q; Chen Q; Wang H; Zhou H; He Y; Pan S; Yin J
Crit Care; 2019 May; 23(1):195. PubMed ID: 31151471
[TBL] [Abstract][Full Text] [Related]
35. Gut Microbiome in Probable Intestinal Tuberculosis and Changes following Anti-Tuberculosis Treatment.
Yoon H; Park YS; Shin CM; Kim N; Lee DH
Yonsei Med J; 2022 Jan; 63(1):34-41. PubMed ID: 34913282
[TBL] [Abstract][Full Text] [Related]
36. The impact of early-life antibiotics and probiotics on gut microbial ecology and infant health outcomes: a Pregnancy and Birth Cohort in Northwest China (PBCC) study protocol.
Qi Q; Wang L; Gebremedhin MA; Li S; Wang X; Shen J; Zhu Y; Andegiorgish AK; Cheng Y; Shi L; Zhou J; Yang Y; Kang Y; Yang W; Zhu Z; Zeng L
BMC Pediatr; 2022 Dec; 22(1):738. PubMed ID: 36577993
[TBL] [Abstract][Full Text] [Related]
37. The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide.
Lin HS; Cheng CW; Lin MS; Chou YL; Chang PJ; Lin JC; Ye JJ
Clin Interv Aging; 2016; 11():299-306. PubMed ID: 27042029
[TBL] [Abstract][Full Text] [Related]
38. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
39. Dynamic construction of gut microbiota may influence allergic diseases of infants in Southwest China.
Shen X; Wang M; Zhang X; He M; Li M; Cheng G; Wan C; He F
BMC Microbiol; 2019 Jun; 19(1):123. PubMed ID: 31182034
[TBL] [Abstract][Full Text] [Related]
40. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
